Fig. 3.

Projected impact of annual and biannual targeted preventive chemotherapy with and without ivermectin co-administration on the prevalence of heavy T. trichiura infections in children. The solid and dotted line pertain to standalone albendazole, and albendazole–ivermectin co-administration respectively. Two different transmission settings were explored; lower (R₀ = 1.25), and higher (R₀ = 1.75 — fitted). Results assume 75% treatment coverage of Pre-SAC and SAC. The drug efficacy was assumed to be 50% for standalone albendazole (Vercruysse et al., 2011a), and 95% when co-administering ivermectin (Speich et al., 2015). Note that those under five years of age cannot receive ivermectin and would only be treated with albendazole. The results assume the lower intensity thresholds for heavy infection (presented in Table 1). The corresponding results using the higher intensity threshold are presented in Supporting Fig. S2. ALB; Albendazole, IVM; Ivermectin.